Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to find an optimized initial regimen for pulmonary tuberculosis(PTB), evaluating the efficacy, safety and acceptability of isoniazid, rifampicin and moxifloxacin(HRM) for the intensive phase of initial therapy of PTB, compared with the standard initial regimen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

NCT06917495

Mild Spinal Tuberculosis

NOT_YET_RECRUITING PHASE2

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

NCT05454345

Tuberculosis, Pulmonary

NOT_YET_RECRUITING PHASE3

Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

NCT05401071

Tuberculosis, Pulmonary

RECRUITING PHASE2/PHASE3

Efficacy and Safety of Intravenous Treatment of Tuberculosis

NCT04150367

Tuberculosis, Pulmonary

TERMINATED

Latency in Pulmonary Tuberculosis

NCT01154959

Pulmonary Tuberculosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The standard initial regimen for PTB consists of an initial 2-month intensive phase followed by a 4-month continuation phase. In the initial 2-month intensive phase, patients have to take four drugs-isoniazid, rifampin, pyrazinamide and ethambutol (HRZE) which might cause many adverse reactions. During the intensive phase, patients are prone to poor compliance due to adverse reactions, resulting in poor outcomes and drug-resistance. Therefore, it is necessary to optimize the regimen of intensive phase to improve patients' medication compliance, so as to avoid patients' treatment failure or drug resistance.

Moxifloxacin(M) has high antibacterial activity against both intracellular and extracellular Mycobacterium tuberculosis (Mtb) with few adverse reactions and is the most promising alternative to first-line anti-TB drugs. Isoniazid and rifampin have a strong bactericidal effect on both intracellular and extracellular Mtb. In the initial regimen for PTB, isoniazid and rifampin should be used throughout the whole process. They are the key drugs to ensure the curative effect and prevent recurrence, can not be easily replaced. But pyrazinamide and ethambutol just be used in the intensive phase. Pyrazinamide has the strongest killing effect on the intracellular Mtb and mainly exerts its antibacterial effect in the first two months of treatment. Ethambutol is a bacteriostatic drug, mainly effective for rapidly growing Mtb outside cells. They can lead to severe gastrointestinal reactions, liver damage, papilledema and other adverse reactions. So moxifloxacin might be an optional substitute for pyrazinamide and ethambutol.

This study will involve comparisons that are designed to assess the short-term efficacy, safety, relapse rate one year after drug withdrawal and patients' compliance when substituting moxifloxacin for pyrazinamide and ethambutol in the existing standard regimen. Patients selected for the study will be allocated to the trial group or the control group randomly. The control group will be given six months of a standard regimen(2HRZE/4HR). The trial group will be given a total of six months of treatment, with Substitution of pyrazinamide and ethambutol with moxifloxacin during the intensive phase(2HRM/4HR).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regimen 1: 2HRM/4HR

Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.

Group Type EXPERIMENTAL

Moxifloxacin, Isoniazid, Rifampicin

Intervention Type DRUG

Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.

All treatment is taken daily, for a duration of up to 6 months depending on treatment arm.

Regimen 2: 2HRZE/4HR (control regimen)

Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.

Group Type ACTIVE_COMPARATOR

Rifampicin,Isoniazid,Pyrazinamide,Ethambutol

Intervention Type DRUG

Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.

All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxifloxacin, Isoniazid, Rifampicin

Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.

All treatment is taken daily, for a duration of up to 6 months depending on treatment arm.

Intervention Type DRUG

Rifampicin,Isoniazid,Pyrazinamide,Ethambutol

Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.

All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avelox, Myambutol, Nydrazid, Rifampin, Rifadin Myambutol,Nydrazid,Rifampin,Rifadin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years or over, and an individual who completely bear the ability of civil actions.
* New cases of pulmonary tuberculosis. No previous anti-tuberculosis therapy or cumulatively taking anti-tuberculosis drugs for less than 1 month.
* Pulmonary tuberculosis patients with bacteriological diagnosis.

Exclusion Criteria

* Suffering from tuberculous pleurisy.
* Patients with extrapulmonary tuberculosis.
* Renal insufficiency patients with creatinine clearance rate \<30 ml/min.
* Abnormal liver function (ALT and/or AST and/or TBIL greater than 2 times the upper limit of normal) or decompensated cirrhosis.
* HIV-Ab positive.
* Psychiatric patients, or have a previous history of mental illness, or recently have obvious anxiety or depression and other mental abnormalities.
* Patients receiving immunosuppressive therapy.
* Pregnant or breast feeding.
* Diabetes.
* X-pert MTB/RIF test of sputum or alveolar lavage fluid showed that Mycobacterium tuberculosis was rifampin resistant.
* Moxifloxacin was used within 14 days before entering the group.
* Anti-tuberculosis treatment has been started and drugs are being taken before entering the group.
* QT interval extension \> 480 ms.
* Combined with serious cardiovascular, liver, kidney, nervous system, blood system and other diseases or tumor diseases.
* Pulmonary lesions are widespread with respiratory insufficiency.
* Any other circumstances in which the anti-tuberculosis scheme of the experimental group or the control group cannot be selected for treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Li Ding

Associate chief physician of infectious diseases

Responsibility Role PRINCIPAL_INVESTIGATOR